Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Subcutaneously Administered CAMPATH in CD52 Expressing Hematologic Malignancies

This study has been terminated.
Information provided by:
Sanofi Identifier:
First received: June 3, 2005
Last updated: February 4, 2014
Last verified: February 2014
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: September 2005
  Estimated Primary Completion Date: No date given